The DOI matches its Crossref record; 41 of the 41 references it cites were found in a registry or an index.
Natalizumab for Multiple Sclerosis
Abstract
A 30-year-old woman with relapsing–remitting multiple sclerosis presents for consideration of treatment with natalizumab after several first-line treatments have failed. Natalizumab has been shown to reduce the rates of relapse and disease progression in multiple sclerosis. However, use of this agent is restricted because of the risk of progressive multifocal leukoencephalopathy, a serious central nervous system disorder.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A Randomized, Placebo-Controlled Trial of Natalizumab for Relapsing Multiple Sclerosis
Polman, C. H., O'Connor, P. W., Havrdova, E., Hutchinson, M., Kappos, L., Miller, D. H., Phillips, J. T., Lublin, F. D., Giovannoni, G., Wajgt, A., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa044397 · Cited by 3,386
Cortical demyelination and diffuse white matter injury in multiple sclerosis
Kutzelnigg, A., Lucchinetti, C. F., Stadelmann, C., Brück, W., Rauschka, H., Bergmann, M., Schmidbauer, M., Parisi, J. E., & Lassmann, H. (2005) · Brain · doi:10.1093/brain/awh641 · Cited by 1,836
Multiple Sclerosis — The Plaque and Its Pathogenesis
Frohman, E. M., Racke, M. K., & Raine, C. S. (2006) · New England Journal of Medicine · doi:10.1056/nejmra052130 · Cited by 1,740
Natalizumab plus Interferon Beta-1a for Relapsing Multiple Sclerosis
Rudick, R. A., Stuart, W. H., Calabresi, P. A., Confavreux, C., Galetta, S. L., Radue, E.-W., Lublin, F. D., Weinstock-Guttman, B., Wynn, D. R., Lynn, F., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa044396 · Cited by 1,344
Kleinschmidt-DeMasters, B. K., & Tyler, K. L. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa051782 · Cited by 1,072
Progressive Multifocal Leukoencephalopathy after Natalizumab Therapy for Crohn's Disease
Van Assche, G., Van Ranst, M., Sciot, R., Dubois, B., Vermeire, S., Noman, M., Verbeeck, J., Geboes, K., Robberecht, W., & Rutgeerts, P. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa051586 · Cited by 1,060
Evaluation of Patients Treated with Natalizumab for Progressive Multifocal Leukoencephalopathy
Yousry, T. A., Major, E. O., Ryschkewitsch, C., Fahle, G., Fischer, S., Hou, J., Curfman, B., Miszkiel, K., Mueller-Lenke, N., Sanchez, E., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa054693 · Cited by 790
The Neurobiology of Multiple Sclerosis: Genes, Inflammation, and Neurodegeneration
Hauser, S. L., & Oksenberg, J. R. (2006) · Neuron · doi:10.1016/j.neuron.2006.09.011 · Cited by 776
The ins and outs of T-lymphocyte trafficking to the CNS: anatomical sites and molecular mechanisms
Engelhardt, B., & Ransohoff, R. M. (2005) · Trends in Immunology · doi:10.1016/j.it.2005.07.004 · Cited by 673
Self-citationEpstein-Barr Virus Antibodies and Risk of Multiple Sclerosis: A Prospective Study
Ascherio, A., Munger, K. L., Lennette, E. T., Spiegelman, D., Hernán, M. A., Olek, M. J., Hankinson, S. E., & Hunter, D. J. (2001) · JAMA · doi:10.1001/jama.286.24.3083 · Cited by 549
Steinman, L., & Zamvil, S. S. (2006) · Annals of Neurology · doi:10.1002/ana.20913 · Cited by 479
Levin, L. I. (2005) · JAMA · doi:10.1001/jama.293.20.2496 · Cited by 448
Immune surveillance in multiple sclerosis patients treated with natalizumab
Stüve, O., Marra, C. M., Jerome, K. R., Cook, L., Cravens, P. D., Cepok, S., Frohman, E. M., Phillips, J. T., Arendt, G., Hemmer, B., et al. (2006) · Annals of Neurology · doi:10.1002/ana.20858 · Cited by 434
Natalizumab treatment for multiple sclerosis: recommendations for patient selection and monitoring
Kappos, L., Bates, D., Hartung, H.-P., Havrdova, E., Miller, D., Polman, C. H., Ravnborg, M., Hauser, S. L., Rudick, R. A., Weiner, H. L., et al. (2007) · The Lancet Neurology · doi:10.1016/s1474-4422(07)70078-9 · Cited by 421
Costs and quality of life of patients with multiple sclerosis in Europe
Kobelt, G. (2006) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.2006.090365 · Cited by 363
Hafler, D. A. (2004) · Journal of Clinical Investigation · doi:10.1172/jci21357 · Cited by 315
Anti-α4 integrin therapy for multiple sclerosis: Mechanisms and rationale
Rice, G. P. A., Hartung, H.-P., & Calabresi, P. A. (2005) · Neurology · doi:10.1212/01.wnl.0000158329.30470.d0 · Cited by 305
Scott, L. M., Priestley, G. V., & Papayannopoulou, T. (2003) · Molecular and Cellular Biology · doi:10.1128/mcb.23.24.9349-9360.2003 · Cited by 301
Costs and quality of life in multiple sclerosis: A cross-sectional study in the United States
Kobelt, G., Berg, J., Atherly, D., & Hadjimichael, O. (2006) · Neurology · doi:10.1212/01.wnl.0000218309.01322.5c · Cited by 286
α4Integrins as Therapeutic Targets in Autoimmune Disease
von Andrian, U. H., & Engelhardt, B. (2003) · New England Journal of Medicine · doi:10.1056/nejme020157 · Cited by 276
Stüve, O., Marra, C. M., Bar-Or, A., Niino, M., Cravens, P. D., Cepok, S., Frohman, E. M., Phillips, J. T., Arendt, G., Jerome, K. R., et al. (2006) · Archives of Neurology · doi:10.1001/archneur.63.10.1383 · Cited by 271
Progressive multifocal leukoencephalopathy revisited: Has the disease outgrown its name?
Koralnik, I. J. (2006) · Annals of Neurology · doi:10.1002/ana.20933 · Cited by 243
High seroprevalence of Epstein–Barr virus in children with multiple sclerosis
Pohl, D., Krone, B., Rostasy, K., Kahler, E., Brunner, E., Lehnert, M., Wagner, H. J., Gärtner, J., & Hanefeld, F. (2006) · Neurology · doi:10.1212/01.wnl.0000247665.94088.8d · Cited by 226
Defining interferon β response status in multiple sclerosis patients
Rudick, R. A., Lee, J., Simon, J., Ransohoff, R. M., & Fisher, E. (2004) · Annals of Neurology · doi:10.1002/ana.20224 · Cited by 217
Self-citationModification of MRI criteria for multiple sclerosis in patients with clinically isolated syndromes
Swanton, J. K. (2006) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.2005.073247 · Cited by 200
The mechanism of action of methylprednisolone in the treatment of multiple sclerosis
Sloka, J. S., & Stefanelli, M. (2005) · Multiple Sclerosis Journal · doi:10.1191/1352458505ms1190oa · Cited by 195
Longitudinal follow-up of “benign” multiple sclerosis at 20 years
Sayao, A., Devonshire, V. A., & Tremlett, H. L. (2007) · Neurology · doi:10.1212/01.wnl.0000253185.03943.66 · Cited by 158
Ransohoff, R. M. (2005) · Nature Neuroscience · doi:10.1038/nn1005-1275 · Cited by 141
Self-citationKorteweg, T., Tintoré, M., Uitdehaag, B. M. J., Rovira, À., Frederiksen, J. L., Miller, D. H., Fernando, K., Filippi, M., Agosta, F., Rocca, M. A., et al. (2006) · The Lancet Neurology · doi:10.1016/s1474-4422(06)70353-2 · Cited by 134
Multiple sclerosis is linked to Epstein‐Barr virus infection
HAAHR, S., & Höllsberg, P. (2006) · Reviews in Medical Virology · doi:10.1002/rmv.503 · Cited by 128
Frohman, E. M., Filippi, M., Stüve, O., Waxman, S. G., Corboy, J. R., Phillips, J. T., Lucchinetti, C. F., Wilken, J. A., Karandikar, N. J., Hemmer, B., et al. (2005) · Archives of Neurology · doi:10.1001/archneur.62.9.1345 · Cited by 125
The role of MRI in the diagnosis of multiple sclerosis.
Traboulsee, A. L., & Li, D. K. B. (2006) · PubMed · Cited by 110
Multiple Sclerosis: The Problem of Incorrect Diagnosis
Rudick, R. A. (1986) · Archives of Neurology · doi:10.1001/archneur.1986.00520060042015 · Cited by 83
Current approved options for treating patients with multiple sclerosis
Rizvi, S., & Agius, M. A. (2004) · Neurology · doi:10.1212/wnl.63.12_suppl_6.s8 · Cited by 77
Multiple sclerosis: advances in understanding, diagnosing, and treating the underlying disease.
Fox, R., Bethoux, F., Goldman, M., & Cohen, J. A. (2006) · Cleveland Clinic journal of medicine · doi:10.3949/ccjm.73.1.91 · Cited by 75
Not Every Patient With Multiple Sclerosis Should Be Treated at Time of Diagnosis
Pittock, S. J., Weinshenker, B. G., Noseworthy, J. H., Lucchinetti, C. F., Keegan, M., Wingerchuk, D. M., Carter, J., Shuster, E. A., & Rodriguez, M. (2006) · Archives of Neurology · doi:10.1001/archneur.63.4.611 · Cited by 62
Multiple sclerosis, natalizumab therapy, and progressive multifocal leukoencephalopathy
Bartt, R. E. (2006) · Current Opinion in Neurology · doi:10.1097/01.wco.0000236612.66839.a2 · Cited by 51
Selective Treatment of Multiple Sclerosis
Ropper, A. H. (2006) · New England Journal of Medicine · doi:10.1056/nejme068002 · Cited by 47
Infusion-related hypersensitivity reactions during natalizumab treatment
Phillips, J. T., O'Connor, P. W., Havrdová, E., Hutchinson, M., Kappos, L., Miller, D., Polman, C. H., LUBLIN, F. D., Giovannoni, G., Wajgt, A., et al. (2006) · Neurology · doi:10.1212/01.wnl.0000242629.66372.33 · Cited by 43
Non-specific immunosuppressants in the treatment of multiple sclerosis
Confavreux, C., & Vukusic, S. (2004) · Clinical Neurology and Neurosurgery · doi:10.1016/j.clineuro.2004.02.012 · Cited by 31
Aspects of multiple sclerosis that relate to trial design and clinical management
(2007) · CRC Press eBooks · doi:10.3109/9780203012055-3 · Cited by 12
Cited by
The Blood-Brain Barrier in Health and Chronic Neurodegenerative Disorders
Zlokovic, B. V. (2008) · Neuron · doi:10.1016/j.neuron.2008.01.003 · Cited by 3,280
Microglial physiology: unique stimuli, specialized responses
Ransohoff, R. M., & Perry, V. H. (2009) · Annual Review of Immunology · doi:10.1146/annurev.immunol.021908.132528 · Cited by 1,858
Self-citationThe safety and side effects of monoclonal antibodies
Hansel, T. T., Kropshofer, H., Singer, T., Mitchell, J. A., & George, A. J. T. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd3003 · Cited by 1,144
The anatomical and cellular basis of immune surveillance in the central nervous system
Ransohoff, R. M., & Engelhardt, B. (2012) · Nature Reviews Immunology · doi:10.1038/nri3265 · Cited by 972
Self-citationMultiple Sclerosis: Current and Emerging Disease-Modifying Therapies and Treatment Strategies
Wingerchuk, D. M., & Carter, J. L. (2014) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2013.11.002 · Cited by 416
Metadata
- Authors
- Ransohoff, R. M.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2007-06-21
- Volume
- 356
- Issue
- 25
- Pages
- 2622-2629
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W1989037087
- Cited by
- 253
- References
- 41
- FWCI
- 14.92
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.